An early study, aimed at determining whether excessive EGFR signalling can induce gliomas in vivo, employed the RCAS vector system to introduce an Egfr activating mutation (the EgfrvIII deletion and second deletion that removes the intracellular regulatory kinase domain) in mice expressing the avian tumour virus receptor A (TVA) under control of brain cell specific promoters (nestin and glial fibrillary acidic protein (GFAP)). This evidence concerns the gene GFAP and glioma.